Tag Archives: biotech industry

Picks and Pans – The Buy-Side View for 2012

Survey

What’s the forecast for biotech in 2012? Do investors think it is a good time to invest in biotechnology? Are they interested in taking on early stage companies? At the BIO CEO & Investor Conference opening plenary, the BIO Industry Analysis team released results from their Investor Perception Study and, afterwards, a panel of portfolio managers and senior buy-side analysts fielded a range of question about the challenges and opportunities facing the industry. David Gluckman, M.D., Read More >

Events  |  1 Comment  |  Email This Post
Tags: , , , , ,

Fireside Chat with Moncef Slaoui, GlaxoSmithKline

Dr. Moncel Slaoui

Moncel Slaoui, chairman of research and development (R&D) at GlaxoSmithKline (GSK), opened the 2012 BIO CEO & Investor Conference with a Fireside Chat where he provided insight in to his company’s biopharma R&D strategy. “GSK has announced that our R&D budget is no more a percentage of sales. If you think about it, it doesn’t make sense,” Slaoui stated, “because, sales are a marker of R&D 10 and 15 years ago.” Right now, GSK has Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Managing in a Cost-Constrained Environment

medicine

By Jill E. Sackman, D.V.M., Ph.D., Senior Consultant, and Matt Levy, J.D., Business Analyst, at Numerof & Associates, Inc. (NAI) The pharmaceutical industry has entered a critical period of transition. Business models that have proven remarkably successful over the past 20 years are now encountering major challenges. As biotech companies grapple with the leading symptoms of these challenges – pricing pressures, pipeline productivity concerns, a growing public distrust, and greater political and regulatory scrutiny – Read More >

Business of Biotech  |  1 Comment  |  Email This Post
Tags: , , , , ,

2012 BIO International Convention to Highlight Breakthroughs

sarah-thumb

2012 BIO International Convention to Highlight Breakthroughs in Healing, Fueling, and Feeding the World The BIO International Convention Program Committee recently selected 125 thought-provoking and timely sessions among 13 educational tracks. The 2012 tracks include: Achieving Regulatory Approval and Compliance; Biofuels and Biobased Chemicals; Biotech Patenting and Tech Transfer; Business Development; Drug Discovery and Development; Finance; Food and Agriculture; Global Innovation and Markets; Health Policy and Reimbursement; Innovations in Vaccines; International Case Studies; Manufacturing of Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,

Sizing up the NBI in 2011

How did the Nasdaq Biotechnology Index (NBI) perform in 2011 relative to other sectors? Second place. Not so bad considering 2011 was the year of defense in the stock market. Like a page out of a textbook on defensive market plays, utilities edged out ahead with a +15% gain, followed by consumer staples with 11%. The NBI squeezed in between at 12%, just above the overall healthcare sector. Overall, the S&P500 was flat for the Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,